LAUSR

I read with interest the article by Martinez et al. entitled “Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry” published in Curr Med Res Opin. This work determined the rates of stroke, nonfatal myocardial infarction, major bleeding, intracranial bleeding and death in a Spanish cohort of 732 patients. This topic is of great interest; therefore, I would like to make some comments. I agree with the following conclusions of the authors: rates of stroke and bleeding were closer to those reported in the ROCKET-AF trial than those in the XANTUS study, but similar to those reported in the Dresden NOAC Registry. There are several issues with their present analysis that may impact the overall findings of their paper.